We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+27.74%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$1.71B
AUM Growth
+$107M
Cap. Flow
-$183M
Cap. Flow %
-10.67%
Top 10 Hldgs %
37.71%
Holding
102
New
9
Increased
24
Reduced
36
Closed
9

Top Buys

Rank Stock Value
1
HTFL
Heartflow Inc
HTFL
+$8.04M
2
CDTX
Cidara Therapeutics
CDTX
+$7.36M
3
LENZ
LENZ Therapeutics
LENZ
+$5.6M
4
TVTX icon
Travere Therapeutics
TVTX
+$4.82M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.15M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$30.4M
2
BPMC
Blueprint Medicines
BPMC
+$23.8M
3
ARGX icon
argenx
ARGX
+$21.8M
4
INSM icon
Insmed
INSM
+$17.2M
5
UNH icon
UnitedHealth
UNH
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.66%
2 Miscellaneous 1.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$62.3B
$105M 6.15%
142,750
-33,000
-19% -$21.8M
LLY icon
2
Eli Lilly
LLY
$1.03T
$80.4M 4.7%
105,400
-11,100
-10% -$8.26M
RYTM icon
3
Rhythm Pharmaceuticals
RYTM
$6.82B
$72.4M 4.23%
717,102
-144,051
-17% -$13.4M
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$12.3B
$63.2M 3.69%
137,746
-2,550
-2% -$951K
RVMD icon
5
Revolution Medicines
RVMD
$42.2B
$62.4M 3.64%
1,335,270
+4,310
+0.3% +$169K
MRUS
6
DELISTED
Merus
MRUS
$56.2M 3.28%
597,051
-466,557
-44% -$30.4M
MIRM icon
7
Mirum Pharmaceuticals
MIRM
$6.42B
$55.8M 3.26%
761,126
-57,080
-7% -$3.63M
INSM icon
8
Insmed
INSM
$27.1B
$55.4M 3.24%
385,000
-140,000
-27% -$17.2M
TVTX icon
9
Travere Therapeutics
TVTX
$6.1B
$51.7M 3.02%
2,164,773
+256,565
+13% +$4.82M
ASND icon
10
Ascendis Pharma A/S
ASND
$15.7B
$42.6M 2.49%
214,500
-2,500
-1% -$466K
IRTC icon
11
iRhythm Holdings
IRTC
$3.68B
$40.4M 2.36%
235,000
-7,500
-3% -$1.19M
AGIO icon
12
Agios Pharmaceuticals
AGIO
$2.01B
$38.5M 2.25%
958,542
-31,203
-3% -$1.17M
RARE icon
13
Ultragenyx Pharmaceutical
RARE
$1.43B
$37.5M 2.19%
1,246,341
-144,731
-10% -$4.34M
ISRG icon
14
Intuitive Surgical
ISRG
$135B
$36.7M 2.14%
82,000
– –
BSX icon
15
Boston Scientific
BSX
$63.1B
$35.2M 2.06%
360,250
+5,250
+1% +$544K
XENE icon
16
Xenon Pharmaceuticals
XENE
$5.55B
$34.2M 2%
851,744
-79,937
-9% -$2.82M
ALNY icon
17
Alnylam Pharmaceuticals
ALNY
$32.9B
$33.9M 1.98%
74,250
-25,750
-26% -$10.5M
EXAS
18
DELISTED
Exact Sciences
EXAS
$32.5M 1.9%
593,500
+21,500
+4% +$1.07M
PEN icon
19
Penumbra
PEN
$12.6B
$30.5M 1.78%
120,500
-8,000
-6% -$2.02M
AKRO
20
DELISTED
Akero Therapeutics
AKRO
$29.7M 1.74%
626,526
-14,000
-2% -$678K
SRRK icon
21
Scholar Rock
SRRK
$5.97B
$29.6M 1.73%
794,133
– –
ZLAB icon
22
Zai Lab
ZLAB
$2.9B
$26.8M 1.57%
791,193
-80,199
-9% -$2.76M
GPCR icon
23
Structure Therapeutics
GPCR
$2.5B
$26.6M 1.56%
951,154
-184,725
-16% -$3.68M
KYMR icon
24
Kymera Therapeutics
KYMR
$9.85B
$25.5M 1.49%
450,374
– –
THC icon
25
Tenet Healthcare
THC
$21.1B
$25.4M 1.48%
125,000
-5,000
-4% -$887K
1
2 3 4 5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Rock Springs Capital Management held 102 positions worth $1.71B, up 6.7% from $1.6B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Rock Springs Capital Management withdrew a net $183M in Q3 2025, closing 9 positions and reducing 36 holdings. Its most notable exit was Blueprint Medicines, an estimated $23.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Rock Springs Capital Management opened a new position in Heartflow Inc worth $8.41M.

  • Rock Springs Capital Management's largest Q3 2025 buy was Heartflow Inc: 250,000 shares worth $8.41M.
  • Rock Springs Capital Management added most to Cidara Therapeutics in Q3 2025, an estimated $7.36M increase.
  • Rock Springs Capital Management's biggest Q3 2025 reduction was Merus, cutting an estimated $30.4M.
  • Rock Springs Capital Management fully exited Blueprint Medicines in Q3 2025, selling an estimated $23.8M.
  • Rock Springs Capital Management's ten largest holdings make up 38% of its $1.71B portfolio in Q3 2025.
  • Rock Springs Capital Management opened 9 new positions and closed 9 in Q3 2025.
  • Rock Springs Capital Management's portfolio value rose 6.7% quarter-over-quarter to $1.71B.

Based on Rock Springs Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.